--- title: "Nektar sets one-for-fifteen reverse split, effective June 8, 2025" url: "https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-06-04" section: "Listings" tickers: "NASDAQ:NKTR" source: "https://www.sec.gov/Archives/edgar/data/906709/000121390025051191/ea0244011-8k_nektar.htm" summary: "Nektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split," --- By the aibio.space news desk. Sources - [Nektar Therapeutics 8-K (2025-06-04)](https://www.sec.gov/Archives/edgar/data/906709/000121390025051191/ea0244011-8k_nektar.htm) - [Nektar Therapeutics 8-K (2025-06-06)](https://www.sec.gov/Archives/edgar/data/906709/000121390025052141/ea0244929-8k_nektar.htm) [NKTR](https://aibio.space/companies/nektar-therapeutics/) 2025-06-04 # Nektar sets one-for-fifteen reverse split, effective June 8, 2025 Tickers [NKTR](https://aibio.space/companies/nektar-therapeutics/) Nektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000. ## Key facts - **Company**: Nektar Therapeutics (NASDAQ: NKTR) - **News type**: Listings - **Primary source**: [Nektar Therapeutics 8-K (2025-06-04)](https://www.sec.gov/Archives/edgar/data/906709/000121390025051191/ea0244011-8k_nektar.htm) *Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.* Nektar Therapeutics (Nasdaq: [NKTR](https://aibio.space/companies/nektar-therapeutics/)) said in an 8-K dated June 4, 2025 that its board approved a one-for-fifteen reverse stock split of its common stock on May 23, 2025. The split is expected to become effective at 11:59 p.m. Eastern Time on June 8, 2025. Shares are to begin trading on a split-adjusted basis at market open on June 9, 2025, under the existing symbol "NKTR" and a new CUSIP number, 640268306. Chief Legal Officer and Secretary Mark A. Wilson signed the filing. ### How the split works Stockholders approved the reverse split at the annual meeting on May 23, 2025. The vote allowed the board to pick a ratio between 1-for-2 and 1-for-40, at its sole discretion, on or before May 23, 2026. The board chose 1-for-15 the same day as the vote. Every fifteen shares of common stock outstanding just before the effective time will be converted automatically into one share. No fractional shares will be issued. Fractions will be rounded up at the participant level with The Depository Trust Company if the shares are held directly. Fractions on shares subject to an award granted under the 2017 Amended and Restated Performance Incentive Plan will be rounded down to the nearest whole share. The 8-K does not say why the board chose a reverse split or whether a Nasdaq listing requirement prompted it. It gives no figure for shares outstanding before or after the split and no share price. ### The June 6 certificates In a later 8-K dated June 6, 2025, Nektar said it filed two certificates of amendment to its Certificate of Incorporation with the Delaware Secretary of State that day. The first raised authorized common shares from 300,000,000 to 390,000,000. Stockholders had approved that increase at the same May 23 annual meeting, and it took effect on filing. The second effected the one-for-fifteen split, effective as of 11:59 p.m. Eastern Time on June 8, 2025. The June 6 filing says the reverse split will not change the number of authorized shares, which stay at 390,000,000 after the increase. A reverse split shrinks the number of shares outstanding, but the ceiling on shares the company may issue does not move with it. The filing does not say whether Nektar plans to issue any of the added shares. ### The business behind the stock The 10-K filed March 14, 2025 describes a pipeline built around rezpegaldesleukin, NKTR-255 and NKTR-0165. Nektar says research and development spending on rezpegaldesleukin rose significantly in 2024 because of two Phase 2b studies, one in moderate-to-severe atopic dermatitis that began in October 2023 and one in severe-to-very severe alopecia areata that began in March 2024. Its figures include Nektar's 25% share of the costs Eli Lilly incurred on Phase 1b and Phase 2 work before the Lilly collaboration agreement was terminated in 2023. Lilly was responsible for 75%. For NKTR-255, spending fell in 2024 because development activity was reduced. The company expected it to fall again in 2025, since it had completed its Phase 2 study in patients with large B-cell lymphoma. For NKTR-0165, Nektar began IND enabling activities in 2024 after exercising, in December 2023, an option for an exclusive license to specified agonistic antibodies from Biolojic Design, Ltd. Nektar also describes a 2023 restructuring plan that reduced its San Francisco-based workforce by approximately 60%, substantially completed by June 2023. Under that plan it decided to sublease its remaining office and laboratory space on Mission Bay Blvd. South. ### What the filings leave open The company says its future clinical trial costs will vary significantly with clinical results and the design, timing and scope of additional programs. It lists the uncertainties it faces, including patient enrollment, trial design requirements from health authorities and competition for patients from other drug candidates studied in the same setting. Nektar says it expects 2025 research and development expense to be consistent with 2024, excluding any added rezpegaldesleukin work that depends on the Phase 2b results. Neither June filing includes financial figures, so the reverse split itself changes no reported balance. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story NKTR Nektar Therapeutics NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nektar sets one-for-fifteen reverse split, effective June 8, 2025", 2025-06-04, https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/